Schizophrenia
Conditions
Brief summary
This study is intended to determine whether the addition of trospium chloride to xanomeline tartrate will ameliorate the peripheral cholinergic side effects that have been previously experienced with xanomeline tartrate when administered alone.
Detailed description
In this inpatient study, volunteers will received either xanomeline alone, or xanomeline plus trospium for 7 days. Subjects will report cholinergic side effects daily via visual analog scales, for each of nausea, vomiting, diarrhea, sweating and excessive salivation. Clinician administered scales will also be administered daily for assessment of the same cholinergic side effects.
Interventions
DRUGxanomeline tartrate
xanomeline tartrate, 75 mg capsule, TID
trospium chloride, over encapsulated 20 mg tablet, BID
Sponsors
Karuna Therapeutics
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Female subjects must be postmenopausal (at least 2 years prior to dosing) or agree to use an acceptable form of birth control from screening until 14 days after completion of the study. If on birth control pills, have been on a stable dose for≥12 months. * Good general health * Ability to give informed consent and understand verbal instructions * Willingness to spend 10 days in an in-patient facility
Exclusion criteria
* History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the subject or the validity of the study results. (Subjects with any history of resolved cancer that is \>5 years passed can be included.) * Body Mass Index \<18 or \> 40 kg/m2 * History of or high risk of urinary retention, gastric retention, or narrow-angle glaucoma * History of alcohol or drug abuse within the last 24 months, or current abuse as determined by urine toxicology screen * Clinically significant abnormal finding on the physical exam, medical history, ECG, or clinical laboratory results at screening * Has participated in another clinical trial within 90 days prior to the first dose of study medication * Needs to take any prescription medication besides the investigational product or those specifically noted above. Use of any vitamins, herbs, supplements, or over the counter medications are excluded within one week of enrollment, and during the course of the trial. Specifically, subjects may not take Benadryl® for one week prior and during the course of the study. * Use of any tobacco products within the past 30 days * Previous positive test for HIV 1 and/or 2, or Hepatitis A, B, or C, or a positive test obtained at screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean weekly maximum composite Visual Analogue Scale (VAS) score (nausea, diarrhea, sweating, salivation and vomiting combined) comparing xanomeline + placebo to xanomeline + trospium | 7 days |
Countries
United States
Outcome results
None listed